BALA CYNWYD, Pa.--(BUSINESS WIRE)--Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (Nasdaq: ESPR) for potential violations of federal securities laws and breaches of the Esperion Board’s fiduciary duties.
Click here to learn more http://brodsky-smith.com/1042-espr-esperion-therapeutics-inc.html, or call: 877-534-2590. There is no cost or obligation to you.
The investigation concerns a securities class action lawsuit commenced in the United States District Court for the Eastern District of Michigan. The complaint alleges that the Defendants made false and misleading statements including failing to disclose that there was no clear path to approval for ETC-1002, and that the FDA had encouraged the Company to initiate a cardiovascular outcomes trial. According to the complaint, following the September 28, 2015 disclosure of these facts, shares of Esperion stock declined significantly.
If you purchased shares of Esperion common stock between August 18, 2015 and September 28, 2015, and wish to discuss the investigation, or if you have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC by March 14, 2016, who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at email@example.com, by visiting http://brodsky-smith.com/1042-espr-esperion-therapeutics-inc.html, or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders.
Attorney advertising. Prior results do not guarantee a similar outcome.